EDAP Reports Fourth Quarter 2020 Results and Provides Operational Update
March 30, 2021 16:35 ET
|
EDAP TMS S.A.
Generated record fourth quarter revenue of EUR 15.4 million (USD 18.3 million), an increase of 28% year-over-year; HIFU revenue up 51% year-over-yearGenerated €41.7 million revenue and profitable...
EDAP TMS SA to Announce Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021
March 23, 2021 08:00 ET
|
EDAP TMS S.A.
Company to host conference call and webcast on Wednesday, March 31 at 8:30 am EDT LYON, France, March 23, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies,...
EDAP Selects Leading Reimbursement Consultancies MTP and Argenta Advisors to Expand Market Access and Coverage of HIFU in the US
March 03, 2021 08:00 ET
|
EDAP TMS S.A.
Initiatives focused on making HIFU procedures broadly accessible to both Medicare and commercially insured patients LYON, France, March 3, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the...
EDAP Announces Record Preliminary Unaudited Fourth Quarter 2020 Revenue of EUR 15.3 Million [$18.3 million], an Increase of 28% Year-Over-Year
January 20, 2021 08:00 ET
|
EDAP TMS S.A.
Record HIFU revenue growth of 50% in the fourth quarter 2020 driven by the sale of eight HIFU devices sold during the quarter Achieved sequential quarterly revenue growth throughout 2020...
EDAP to Participate in B. Riley Securities Virtual Oncology Investor Conference
January 19, 2021 08:00 ET
|
EDAP TMS S.A.
LYON, France, January 19, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that Marc Oczachowski, President and CEO, will...
EDAP Announces Positive 24 Month Interim Results of French Urology Association (AFU) Sponsored Clinical Study comparing HIFU to Radical Prostate Surgery
January 14, 2021 08:00 ET
|
EDAP TMS S.A.
Results on 3,329 patients demonstrate significant difference in efficacy in favor of HIFU versus Radical Prostatectomy (RP) HIFU treatment also resulted in meaningful benefits in both urinary and...
EDAP Issues Letter to Shareholders
January 06, 2021 08:00 ET
|
EDAP TMS S.A.
Recaps progress made in 2020 notwithstanding the ongoing COVID-19 pandemic and previews anticipated 2021 milestones LYON, France, January 6, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”),...
EDAP to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
January 05, 2021 08:00 ET
|
EDAP TMS S.A.
LYON, France, January 5, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that it will participate in the 10th Annual LifeSci...
EDAP Announces End of the Year Focal One® Sales
December 30, 2020 08:00 ET
|
EDAP TMS S.A.
Among December deals closed, two major US institutions have purchased Focal OneUniversity of California, San Francisco Medical Center and Cleveland Clinic become latest to adopt Focal One high...
EDAP Announces Final U.S. 2021 Reimbursement Rules for High Intensity Focused Ultrasound (HIFU)
December 09, 2020 08:00 ET
|
EDAP TMS S.A.
Final rules establish, for the first time, a Category 1 CPT code and reimbursement to physicians performing ablation of malignant prostate tissue with HIFU in the USPhysician reimbursement for...